Skip to content

Aripiprazole shows comparable efficacy to Haloperidol and better tolerability in paediatric Tic disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN63930220
Enrollment
50
Registered
2008-06-04
Start date
2005-08-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tic disorders Mental and Behavioural Disorders Tic disorders

Interventions

In the aripiprazole group, a child psychiatrist initially prescribed 5.0 mg/d of aripiprazole, and then increased the dose in 5.0 mg/d increments as tolerated at visits every two weeks. The dose was r

Sponsors

Asan Medical Centre (South Korea)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 6 - 18 years 2. Gender: male or female 3. Diagnosis: tic disorders according to the Korean version of the Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (KSADS-PL) 4. Severity: total tic scores greater than or equal to 22 on the Korean version of the Yale Global Tic Severity Scale

Exclusion criteria

Exclusion criteria: 1. Current mood disorders 2. Psychotic symptoms 3. Anxiety disorders except obsessive-compulsive disorder, which is the most common comorbid anxiety disorder in tic patients 4. Subjects with an intelligence quotient (IQ) of 70 or less by using the Korean version of the Wechsler Intelligence Scale for Children-Revised 5. Previous or current seizure episodes, electroencephalogram (EEG) abnormalities 6. Subjects had used aripiprazole previously 7. Any significant medical problems 8. Pregnancy

Design outcomes

Secondary

MeasureTime frame
1. The Clinical Global Impressions-Improvement Scale (CGI-I) 2. The CGI-Severity of Illness Scale (CGI-S) 3. The Extrapyramidal Symptom Rating Scale (ESRS) Both primary and secondary outcomes were measured at every visit (baseline, two weeks, four weeks, six weeks, eight weeks).

Primary

MeasureTime frame
Yale Global Tic Severity Scale (YGTSS): the YGTSS is a semi-structured clinical interview designed to assess current tic severity, which yields three summary scores. Both primary and secondary outcomes were measured at every visit (baseline, two weeks, four weeks, six weeks, eight weeks).

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026